Proprietary Web Technology Reveals Hostility and Anger Among Patients Towards Takeda Pharmaceutical’s ACTOS Diabetes Drug

Share Article

Wool.labs' “Patient Social Intelligence Report” leveraged unique WebDigTM technology to track every conversation accessible on the internet, determining the trends among diabetes patients and healthcare providers as related to diabetes treatment including ACTOS. Conversation data spanned more than a decade and showed that patients’ dissatisfaction levels grew while Takeda Pharmaceuticals and the ACTOS brand did little to try to understand or impact these feelings.

This report demonstrates the mounting evidence that patients are more in control of their decisions than ever before.

Wool.labs(TM), a business intelligence company driven by social cognition technology, has published “The Impact of Social Media on a Brand,” the next study in its subscription series, revealing a negatively-charged dialogue in social media among patients which had grown steadily over time.

The “Patient Social Intelligence Report” leveraged Wool.labs’ unique WebDig(TM) technology to track every conversation accessible on the internet and determined the trends among diabetes patients and healthcare providers as related to diabetes treatment including ACTOS.

Conversation data mined from social media spanned more than a decade and showed that, for the majority of that time, patients’ dissatisfaction levels grew while Takeda Pharmaceuticals and the ACTOS brand did little to try to understand or impact these feelings. The largest gap between patients and physicians interpreting side effects in the same way is seen in 2007.

“In 2007, there is a 47-point difference between patients and physicians in our Awareness and Support Index which means they are not on the same page when it comes to patient frustrations,” says Michele Bennett, Chief Operating Officer of Wool.labs “This may contribute to why prescription volume that year is high as physicians may choose the benefits of ACTOS over patient concerns. However, patients feel that the risks and side effects are not worth the benefits, even if the benefits are great.”

When Takeda launched a switch campaign in 2010 to capitalize on the issues with Avandia (GlaxoSmithKline’s Oral Type 2 Diabetes Medication), social media response was hostile. They believe ACTOS has not truly differentiated itself from Avandia, has not provided proof of a better safety profile in a clear and understandable way, and has not addressed the side effects and risks that are real such as weight gain, edema, CHF, fractures, and bladder cancer.

“This report, like so many others we have run, demonstrates the mounting evidence that patients are more in control of their decisions than ever before,” says Scott Reese, Wool.labs Chief Executive Officer “Industry must learn from them and start paying attention to how they think and feel to avoid irreversible damage to reputation. It is impossible to successfully market to patients if you’re ignoring them. Patients and Physicians are asking important questions and want to be heard.”

The 71-page report “The Impact of Social Media on the Brand” contains patient and physician conversations spanning more than ten years and includes the most representative conversations about the subject area, as well as our analysis of how sentiment has changed over time. To purchase the full report, please visit, http://www.woollabs.com/reportSubscriptions/.

The Patient Social Intelligence Report is a series of retrospective and predictive analyses created by Wool.labs that digs into the hottest topics in the Healthcare and Pharmaceutical industries across a variety of diseases and conditions to understand the sentiment, behavior and beliefs of patients and the impact on business of healthcare.

Wool.labs is a new breed of business intelligence software provider. Our proprietary technology solutions help enterprise clients understand and solve complex business challenges through Social Cognition. We dig deep into dialogue data to uncover core insights and emerging trends to inform strategy, change behavior and drive new business opportunities in a way that is unmatched in the industry.

# # #

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Steve Chiles
Wool.labs
888-966-5527 ext. 777
Email >
Visit website